SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Finerenone plus empagliflozin combination therapy reduces systolic blood pressure in patients with T2D and chronic kidney disease.

Having run the ruler over 140 acquisition proposals, Dimerix has settled on a drug program targeting heart surgery related ...

Cefazolin is noninferior to antistaphylococcal penicillins for methicillin-susceptible Staphylococcus aureus bacteremia and ...

Sonam Wangchuk has been shifted to Safdarjung Hospital and is said to be stable after a 21-day hunger strike, highlighting ...

Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from ...

Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB)Mission will receive up to U ...

Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...

Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist ...

Dimerix expands kidney pipeline with DMX-652 acquisition; Phase 2-ready AKI therapy targets US$3.5b market, upfront US$5m ...

Learn more about whether ADMA Biologics, Inc. or CareDx, Inc. is a better investment based on AAII's A+ Investor grades, ...